http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 15 Jun 2026 09:35:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/BioSyent+to+Present+at+Planet+MicroCap+Las+Vegas/26645287.html <p align="justify">MISSISSAUGA, Ontario, June 15, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Las Vegas investor conference in Las Vegas, Nevada from June 16th to June 18th, 2026 at the Bellagio Hotel. Mr. René Goehrum, President and CEO of BioSyent, will be presenting in person to attendees at the conference on Wednesday, June 17th at 4:00pm PDT.  </p> <p align="justify">Mr. Goehrum will also be meeting with investors on a one-on-one basis during the conference on Wednesday, June 17th and on Thursday, June 18th. Subject http://www.streetinsider.com/Press+Releases/BioSyent+to+Present+at+Planet+MicroCap+Las+Vegas/26645287.html Mon, 15 Jun 2026 09:35:00 -0400 O.02597433 RX http://www.streetinsider.com/Press+Releases/BioSyent+to+Present+at+Planet+MicroCap+Las+Vegas/26645287.html <p align="justify">MISSISSAUGA, Ontario, June 15, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Las Vegas investor conference in Las Vegas, Nevada from June 16th to June 18th, 2026 at the Bellagio Hotel. Mr. René Goehrum, President and CEO of BioSyent, will be presenting in person to attendees at the conference on Wednesday, June 17th at 4:00pm PDT.  </p> <p align="justify">Mr. Goehrum will also be meeting with investors on a one-on-one basis during the conference on Wednesday, June 17th and on Thursday, June 18th. Subject http://www.streetinsider.com/Press+Releases/BioSyent+to+Present+at+Planet+MicroCap+Las+Vegas/26645287.html Mon, 15 Jun 2026 09:35:00 -0400 O.02597433 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+to+Present+at+Planet+MicroCap+Las+Vegas/26645287.html <p align="justify">MISSISSAUGA, Ontario, June 15, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Las Vegas investor conference in Las Vegas, Nevada from June 16th to June 18th, 2026 at the Bellagio Hotel. Mr. René Goehrum, President and CEO of BioSyent, will be presenting in person to attendees at the conference on Wednesday, June 17th at 4:00pm PDT.  </p> <p align="justify">Mr. Goehrum will also be meeting with investors on a one-on-one basis during the conference on Wednesday, June 17th and on Thursday, June 18th. Subject http://www.streetinsider.com/Globe+Newswire/BioSyent+to+Present+at+Planet+MicroCap+Las+Vegas/26645287.html Mon, 15 Jun 2026 09:35:00 -0400 O.02597433 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+to+Present+at+Planet+MicroCap+Las+Vegas/26645287.html <p align="justify">MISSISSAUGA, Ontario, June 15, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Las Vegas investor conference in Las Vegas, Nevada from June 16th to June 18th, 2026 at the Bellagio Hotel. Mr. René Goehrum, President and CEO of BioSyent, will be presenting in person to attendees at the conference on Wednesday, June 17th at 4:00pm PDT.  </p> <p align="justify">Mr. Goehrum will also be meeting with investors on a one-on-one basis during the conference on Wednesday, June 17th and on Thursday, June 18th. Subject http://www.streetinsider.com/Globe+Newswire/BioSyent+to+Present+at+Planet+MicroCap+Las+Vegas/26645287.html Mon, 15 Jun 2026 09:35:00 -0400 O.02597433 RX http://www.streetinsider.com/Corporate+News/BioSyent+receives+Health+Canada+approval+for+levothyroxine+oral+solution/26518886.html <p>BioSyent Inc. (TSX Venture: RX) announced that Health Canada has approved Thyconvi, a levothyroxine oral solution for treating hypothyroidism and thyroid-stimulating hormone suppression. The company states this is the first levothyroxine oral solution available in Canada.</p><p>BioSyent Pharma Inc., a subsidiary of the company, holds exclusive rights to register, market, sell and distribute Thyconvi in Canada. The product contains 20 micrograms of levothyroxine sodium per milliliter and is supplied in packages of two 75-milliliter bottles that do not require refrigeration.</p><p>The oral solution is indicated for hypothyroidism as replacement or supplemental therapy in patients of any age with primary, secondary, and tertiary http://www.streetinsider.com/Corporate+News/BioSyent+receives+Health+Canada+approval+for+levothyroxine+oral+solution/26518886.html Tue, 19 May 2026 09:53:32 -0400 RX http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Press+Releases/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html <p align="justify">MISSISSAUGA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) announces that Health Canada has approved Thyconvi™ (levothyroxine sodium), the first and only levothyroxine oral solution available in Canada for the management of hypothyroidism and thyroid-stimulating hormone (“TSH”) suppression.</p> <p align="justify">BioSyent Pharma Inc., a subsidiary of the Company, has an exclusive license right to register, market, sell and distribute Thyconvi™ in Canada.</p> <p align="justify">“Having a liquid oral levothyroxine option in Canada is a meaningful step forward for hypothyroidism care,” said Dr. Afshan Zahedi, endocrinologist and Medical Director of the Thyroid Program http://www.streetinsider.com/Globe+Newswire/BioSyent+Announces+Health+Canada+Approval+of+Thyconvi%E2%84%A2+%28levothyroxine+oral+solution%29/26518883.html Tue, 19 May 2026 09:52:00 -0400 A.17150087 A.36078215 A.50208808 A.60012013 O.02555813 O.02597433 O.14730341 O.34929518 O.54379156 RX